CAPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
CAPRICOR THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$6.65−0.06 (-0.89%)
Close on Oct 19, 2026
- Market cap
- $385.21M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 747.1% | -78.0% | -46.6% | |
| Return on assets | -108.0% | -59.7% | -39.9% | |
| Current ratio | 3.70 | 11.33 | 9.01 | |
| Debt to equity | – | 0.00 | – | |
| Net debt to EBITDA | – | 2.41× | – | |
| Interest coverage | -49.3× | – | -35.5× | |
| Capex to revenue | 4.8% | 176.5% | – | |
| Diluted shares | 2M | 16M | 46M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Capricor Therapeutics generated $157.13M from operations and spent $8.58M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$157.13M
Used
$8.58M
Capital expenditure$8.58M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-181.7%
×Asset turnover0.19×
×Equity multiplier1.36×
=Return on equity, FY2024-48.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -181.7% | 0.19× | 1.36× | -48.2% |
| FY2023 | -88.5% | 0.46× | 3.16× | -129.6% |
| FY2022 | -1137.4% | 0.06× | 2.12× | -134.5% |
| FY2021 | -8175.9% | 0.01× | 1.28× | -67.2% |
| FY2020 | -4401.9% | 0.01× | 1.31× | -78.0% |
| FY2019 | -760.4% | 0.10× | 1.78× | -133.4% |
| FY2018 | -908.9% | 0.13× | 1.61× | -191.8% |
| FY2017 | 91.2% | 0.15× | 4.85× | 67.3% |
| FY2016 | -470.3% | 0.23× | -6.92× | 747.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$105.04M
- Cash generatingOperating cash flow above zero-$69.81M
- Return on assets improvedROA up on the prior year-68.9% → -61.6%
- Earnings backed by cashOperating cash flow above net income-$69.81M vs -$105.04M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.77 → 9.01
- No dilutionShare count did not rise35M → 46M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.38 → 0.00